"Medical quick reading society" recommended Baiyunshan to resume production of chloroquine phosphate tablets

Novel coronavirus pneumonia was published in February 18, 2020 / medical information As of February 17th, 24 hours: 72436 cases were diagnosed nationwide Who will not raise the global risk level of the new crown pneumonia epidemic situation; Mirati combination therapy has positive clinical results; the first declaration scheme of listed companies refinancing "crow" is active Daily fresh medicine news, speed reading club and you pay attention to! As of 24:00 on February 17, according to the reports of 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang production and Construction Corps, there are 58016 confirmed cases (including 11741 severe cases), 12552 discharged cases (Beijing nuclear increase 7 cases), 1868 dead cases, 72436 confirmed cases (Xinjiang production and Construction Corps nuclear increase 2 cases) and 6242 suspected cases There were 560901 close contacts and 141552 close contacts still under medical observation (official website of National Health Commission) China's new novel coronavirus pneumonia has novel coronavirus pneumonia, which is a new global economic risk level The World Health Organization held a conference in Geneva on 17 March The director general, Tak Desai, said at the meeting that new cases of new crown pneumonia in China were on a downward trend (Xinhua News Agency) Recently, Huoxiang Zhengqi, Jinhua Qinggan granules, Lianhua Qingwen and other Chinese patent medicines have been included in the list of key guarantee materials (medical emergency) for epidemic prevention and control by the Ministry of industry and information technology Recently, the Ministry of industry and information technology released the list of key support materials (medical emergency) for epidemic prevention and control, and Chinese patent medicines such as Huoxiang Zhengqi, Jinhua Qinggan granules and Lianhua Qingwen were recommended (Ministry of industry and information technology of the people's Republic of China) Recently, it has been reported that the clinical scheme of diammonium glycyrrhizinate combined with vitamin C has been put on record by the State Food and drug administration, and the formal clinical trial has been started in Central South Hospital of Wuhan University The research shows that glycyrrhizic acid has a clear antiviral effect and can regulate the immune function to play an antiviral role (cypress blue) As of February 17, China clinical trial registration center alone has registered more than 100 intervention studies on covid-19 The clinical trials of publicly registered investigational drugs for the safety and efficacy of covid-19 are increasing every day There are not only unlisted new drugs such as remdesivir, but also traditional Chinese medicine such as Shuanghuanglian These drug therapies have different amounts of evidence to support their efficacy (medicine cube) The novel coronavirus released a notice on the 17 day that it signed a technical service contract with Guoxin medicine on the randomized, open, parallel, and multicenter clinical trials of "cough fast stop syrup and cough clear capsule" in the treatment of the mild and moderate pneumonia with the effectiveness and safety of the new coronavirus infection (Sina Medical News) On July 17, Shandong provincial centralized procurement platform for medical equipment released information on direct purchase of low-value medical consumables It is pointed out that the direct purchase of low-value medical consumables is based on the e-commerce models of jd.com, tmall.com, etc to build a platform for the production or business enterprises to open stores and display products online, retail pharmacies and individual residents can browse and screen, and directly purchase the low-value medical consumables they need online (cypress blue instrument) On the evening of the 16th, Carling announced the termination of the previously announced plan for non-public issuance of shares in 2019, and disclosed the plan for non-public issuance of shares in 2020 based on the refinancing "new regulations" of listed companies The total amount of new fund-raising is up to 2.3 billion yuan, and the strategic investors introduced are well-known high-level capital in the pharmaceutical industry On the 17th, Carling's share price rose all the way up to the limit (e drug manager) 17, the novel coronavirus pneumonia was introduced by the State Council to press conference on joint prevention and control mechanism In clinic, no matter from a series of indexes, such as the rate of severe disease, the time of improvement of lung image and shortening the course of disease, the drug group is better than the control group (China new network) On July 17, Baiyunshan announced that Guanghua pharmaceutical, its holding subsidiary, had received the approval document for supplementary application of chloroquine phosphate tablets approved and issued by Guangdong Drug Administration It is reported that chloroquine phosphate tablets are mainly used for the treatment of chloroquine sensitive falciparum malaria, Plasmodium vivax and Plasmodium falciparum, and can be used for the prevention of malaria symptoms (Baiyunshan Pharmaceutical announcement) Takeda recently announced the results of the phase III visible 2 clinical trial to evaluate the treatment of Crohn's disease with subcutaneous injection type entyvio at the 2020 annual meeting of Crohn's and colitis organizations in Vienna, Austria The results showed that the study reached the main end point (Biovalley) Recently, mirati company announced the preliminary clinical data of its protein kinase inhibitor sitravatinib combined with anti-PD-1 antibody nivolumab in the treatment of patients with advanced renal clear cell carcinoma in phase 1 / 2 clinical trial Preliminary efficacy data showed that the combination therapy achieved a disease control rate of 92% in this patient group (yaomingkant) Novartis announced Wednesday that the European Commission has approved beovu injection for the treatment of wet age-related macular degeneration Beovu is the first anti VEGF drug approved by the European Union to perform better in reducing retinal fluid compared with eylea Beovu also provides the ability to maintain treatment at 3-month intervals immediately after the loading period in eligible wet amd patients (Sina Medical News) Pharma mar and jazz pharmaceutical 17 jointly announced that the US FDA has accepted its application for priority review of new drugs, seeking to accelerate the approval of lurbinectdin for small cell lung cancer patients who have made progress after previous platinum containing treatment It is reported that FDA has set the target action date of PDUFA as August 16, 2020 (Sina Medical News)